LIMN

Liminatus Pharma, Inc. Class A Common Stock

News

globenewswire.comLiminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceedsglobenewswire.comJun 3

globenewswire.comLiminatus Pharma Announces Nasdaq Delisting Notificationglobenewswire.comMay 21

globenewswire.comLiminatus Pharma Announces Nasdaq Delisting Notificationglobenewswire.comMay 21

feeds.benzinga.comLiminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Sessionfeeds.benzinga.comMay 21

defenseworld.netAthira Pharma (NASDAQ:LONA) and Liminatus Pharma (NASDAQ:LIMN) Head to Head Analysisdefenseworld.netMar 21

About Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.

CEO: Chris Kim
IPO Date: May 1, 2025

Market Data

Open: $0.1183
High: $0.1211
Low: $0.1155
Volume: 702.2K
Avg Volume: 10.1M
52W High: $33.66
52W Low: $0.111

Valuation

Market Cap: $3.2M
Enterprise Value: $2.7M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$10M
Revenue: $0
Net Income: -$10.2M
Cash: $337.7K
Debt: $1.4M

Events

EarningsMay 15

actual -0.03